Upland Rheumatology Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ellis, Amalia
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Perez, Anadelis
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Active, not recruiting
3
450
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
02/26
03/27
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Thompson, Bridgett
DISSOLVE II, NCT04596540: A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

Completed
3
153
US, RoW
SEL-212 low-dose, SEL-212 high-dose, Placebo
Swedish Orphan Biovitrum
Chronic Gout
01/23
01/23
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Guralsky, Lina
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ellis, Amalia
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Perez, Anadelis
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Active, not recruiting
3
450
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
02/26
03/27
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Thompson, Bridgett
DISSOLVE II, NCT04596540: A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

Completed
3
153
US, RoW
SEL-212 low-dose, SEL-212 high-dose, Placebo
Swedish Orphan Biovitrum
Chronic Gout
01/23
01/23
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Guralsky, Lina
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26

Download Options